Associate Professor of Obstetrics and Gynecology, University Wash

Obstetrics & Gynecology

Elizabeth Swisher is an expert in the field of Obstetrics & Gynecology. She over the years received 3 awards: "Regional Top Doctor", "Fellow (FACOG)" and "Super Doctor". Elizabeth Swisher is a published doctor as well. She has 90 publications published. The latest was: Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. She accepts Medicare payments and is listed with Medicare.gov.

Publications

---

• Genetic characterization of early onset ovarian Carcinoma.
• Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
• Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
• More genes, more problems? Benefits and risks of multiplex genetic testing.
• P7.01Characterization of 148 Ovarian Cancer tumografts (Avatars) using BROCA-HR deep sequencing.
• Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development.
• A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, Fallopian tube, or prima...
• DNA repair mutations and outcomes in ovarian Cancer--response.
• Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous Carcinoma.
• Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.
• Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
• Anti-HE4 antibodies in infertile women and women with ovarian Cancer.
• Characteristics of women with ovarian Carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.
• Duration of Cisplatin Excretion in Breast Milk.
• 53BP1 expression in sporadic and inherited ovarian Carcinoma: Relationship to genetic status and clinical outcomes.
• Long term follow up of BRCA1 and BRCA2 mutation carriers With unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
• Loss of function germline mutations in RAD51D in women with ovarian Carcinoma.
• E2F3b over-expression in ovarian Carcinomas and in BRCA1 Haploinsufficient fallopian tube epithelium.
• Angiogenic alterations associated with circulating neoplastic DNA in ovarian Carcinoma.
• BRCA1, TP53, and CHEK2 germline mutations in uterine serous Carcinoma.
• Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
• ColoSeq Provides Comprehensive Lynch and Polyposis Syndrome Mutational Analysis Using Massively Parallel Sequencing.
• Molecular Scores to Predict Ovarian Cancer Outcomes: A Worthy Goal, but Not Ready for Prime Time.
• A self-administered family history questionnaire improves identification of women who warrant referral to genetic counseling for hereditary Cancer risk.
• PAX2 Loss by Immunohistochemistry Occurs Early and Often in Endometrial Hyperplasia.
• Hereditary ovarian Cancer: Beyond the usual suspects.
• BRCA1 and BRCA2 mutations in ovarian Cancer.
• Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal Carcinoma identified by massively parallel sequencing.
• An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.
• Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian Carcinomas.
• Secondary mutations of BRCA1/2 and drug resistance.
• Granulin: biomarker or interesting window into host/tumor biology?
• Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.
• The molecular pathogenesis of hereditary ovarian Carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.
• Detection of the HE4 protein in urine as a biomarker for Ovarian neoplasms.
• BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian Carcinoma.
• Complex hyperplasia With and Without atypia: clinical outcomes and implications of progestin therapy.
• Detection of inherited mutations for breast and ovarian Cancer using genomic capture and massively parallel sequencing.
• MiR-221 and MiR-222 alterations in sporadic ovarian Carcinoma: Relationship to CDKN1B, CDKNIC and overall survival.
• Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian Carcinoma.
• Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal Carcinomas.
• Progestin therapy of complex endometrial hyperplasia With and Without atypia.
• DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian Carcinoma.
• Immunohistochemical markers in endometrial hyperplasia: is there a panel With promise? A review.
• Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian Cancer patients.
• Intratumoral T cells, tumor-Associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian ca...
• Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian Cancers.
• Secondary BRCA1 mutations in BRCA1-mutated ovarian Carcinomas with platinum resistance.
• An evaluation of Cervical cancer in women age sixty and over.
• A psychoeducational intervention for sexual dysfunction in women with gynecologic Cancer.
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated Cancers.
• Defining an appropriate threshold for the diagnosis of serous borderline tumor of the ovary: when is a full staging procedure unnecessary?
• CD83 gene polymorphisms increase susceptibility to human invasive Cervical cancer.
• Alternate molecular genetic pathways in ovarian Carcinomas of common histological types.
• Defining women at high risk of ovarian Cancer.
• Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal Carcinomas.
• Functional characterization of a novel BRCA1-null ovarian Cancer cell line in response to ionizing radiation.
• Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal Carcinoma.
• Cancer biomarkers: a systems approach.
• Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of Cervical cancer: a phase I trial of the Puget Sound Oncology Consortium.
• Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
• The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial Cancer.
• Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast Cancer.
• Does size matter? Tumor size and morphology as predictors of nodal status and recurrence in endometrial Cancer.
• Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian Cancer.
• Comment on "Malignant mixed Mullerian tumor of the ovary: an argument for BRCA3 or a coincidental cluster of unconnected Cancer".
• Follow-up of in situ and early-stage fallopian tube Carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations.
• The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial Cancer.
• Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial Cancers.
• Prophylactic surgery and other strategies for reducing the risk of familial ovarian Cancer.
• Ovarian Cancer associated with inherited mutations in BRCA1 or BRCA2.
• Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
• BRCA1 transcriptionally regulates genes involved in breast tumorigenesis.
• Use of complementary and alternative medicine among women with gynecologic Cancers.
• Hereditary Cancers in obstetrics and gynecology.
• Evaluation of a region on chromosome 1p in ovarian serous Carcinoma that is frequently deleted in uterine papillary serous Carcinoma.
• Occult Cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
• Prophylactic oophorectomy and ovarian Cancer surveillance. Patient perceptions and satisfaction.
• Radical hysterectomy for Cervical cancer in obese women.
• Mutational analysis of the PMS2 gene in sporadic endometrial Cancers with microsatellite instability.
• MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial Cancers.
• Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial Carcinomas with or without microsatellite instability.
• Analysis of MSH3 in endometrial Cancers with defective DNA mismatch repair.
• Metastatic placental site trophoblastic tumor: long-term remission in a patient treated With EMA/CO chemotherapy.
• Topotecan in platinum- and paclitaxel-resistant ovarian Cancer.
• The expression of epidermal growth factor receptor, HER-2/Neu, p53, and Ki-67 antigen in Uterine malignant mixed mesodermal tumors and adenosarcoma.
• Biliary disease during Pregnancy.
• Expression of shared idiotypes in Chronic lymphocytic leukemia and small lymphocytic lymphoma.
• Feasibility of RNA and DNA Extraction from Fresh Pipelle and Archival Endometrial Tissues for Use in Gene Expression and SNP Arrays.

Schools

---

• University of California At San Diego

• University Of Wa School Of Med

Procedures Preformed

---

• C-Section
• Colposcopy
• Destruction or Excision of Vaginal Lesions
• Excision of Cervix
• View All

Conditions Treated

---

• Atrophic Vaginitis
• Carcinoma in Situ
• Cervical Cancer
• Cervical Polyps
• View All

Doctors Specialties

---

• Gynecologic Oncology
• Obstetrics
• Gynecology

Accepted Insurances

---

Awards

---

• Regional Top Doctor
• Fellow (FACOG)
• Super Doctor

Education

---

• University of Washington

Hospital

---

• Seattle Children's Hospital
• University of Washington Medical Center

Drug Facts

---

NPI NUMBER		1902986979
NPPES Provider LastName		SWISHER
NPPES Provider FirstName		ELIZABETH
NPPES Provider ZIPCode		98109
NPPES Provider State		WA
Specialty Description		Gynecological/Oncology
Total Claim Count		28.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1902986979
Last Name Of The Provider	SWISHER
First Name Of The Provider	ELIZABETH
View All

Similar Doctors

---

	Dr. Lauren E. Pray, MD This Doctor is OpenDoctor Recommended.
	Dr. Rebecca A. Kulgren, MD This Doctor is OpenDoctor Recommended.
	Dr. Jeroen P. VanDerhoeven, MD This Doctor is OpenDoctor Recommended.
	Dr. Benjamin E. Greer, MD
	Dr. Dan S. Veljovich, MD This Doctor is OpenDoctor Recommended.
	Dr. Ellen Kauffman, MD This Doctor is OpenDoctor Recommended.
	Dr. Holly R. Sato, MD This Doctor is OpenDoctor Recommended.
	Dr. Amy D. Brockmeyer, MD This Doctor is OpenDoctor Recommended.
	Dr. Jennifer R. Jaucian, MD This Doctor is OpenDoctor Recommended.
	Dr. Edith Y. Cheng, MD This Doctor is OpenDoctor Recommended.
	Dr. Justine Chang, MD This Doctor is OpenDoctor Recommended.
	Dr. Kristina M. Adams Waldorf, MD This Doctor is OpenDoctor Recommended.
	Dr. Kimberly R. Faucher, MD This Doctor is OpenDoctor Recommended.
	Dr. Merry A. Lewis, MD This Doctor is OpenDoctor Recommended.
	Dr. Constance C. Mao, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog